Zhejiang Jolly Pharmaceutical Co Ltd (300181):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Zhejiang Jolly Pharmaceutical Co Ltd (300181) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9383
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Zhejiang Jolly Pharmaceutical Co Ltd (Zhejiang Jolly Pharma) is a producer and marketer of pharmaceutical products. The company offers products in the form of tablets, capsules, granules, injections, dry powders, and others. Its products include Wuling powder, pseudomonas moth powder, cordyceps cephalosporin, powder, Wuling capsule, bailing tablet, azithromycin, doxapram, pefloxacin mesylate and clindamycin phosphate. Zhejiang Jolly Pharma provides Linglianhua particle for menopausal syndrome treatment. The company also adopts medicinal fungi to produce traditional Chinese medicinal products based on bio-fermentation technology. It exports its products to Britain, Singapore, Japan, Malaysia, Croatia, Serbia, Vietnam, Hong Kong, Macao, the US, and other countries. The company operates its subsidiaries in China. Zhejiang Jolly Pharma is headquartered in Huzhou, China.

Zhejiang Jolly Pharmaceutical Co Ltd (300181) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Zhejiang Jolly Pharma Plans to Raise up to USD79 Million in Private Placement of Shares 10
Debt Offering 11
Zhejiang Jolly Pharmaceutical Plans to Raise USD129.5 Million in Private Placement of Bonds Due 2021 11
Zhejiang Jolly Pharma to Raise USD78 Million in Public Offering of Bonds 12
Acquisition 13
Zhejiang Jolly Pharma to Sell 85% Stake in Pharmaceutical Company for USD3.2 Million 13
Zhejiang Jolly Pharma Acquires 27.46% Stake in Baicao Traditional Chinese Medicine 14
Zhejiang Jolly Pharmaceutical Co Ltd – Key Competitors 15
Zhejiang Jolly Pharmaceutical Co Ltd – Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zhejiang Jolly Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Zhejiang Jolly Pharma Plans to Raise up to USD79 Million in Private Placement of Shares 10
Zhejiang Jolly Pharmaceutical Plans to Raise USD129.5 Million in Private Placement of Bonds Due 2021 11
Zhejiang Jolly Pharma to Raise USD78 Million in Public Offering of Bonds 12
Zhejiang Jolly Pharma to Sell 85% Stake in Pharmaceutical Company for USD3.2 Million 13
Zhejiang Jolly Pharma Acquires 27.46% Stake in Baicao Traditional Chinese Medicine 14
Zhejiang Jolly Pharmaceutical Co Ltd, Key Competitors 15

List of Figures
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zhejiang Jolly Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Zhejiang Jolly Pharmaceutical Co Ltd (300181):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Oil India Ltd (OIL):企業の財務・戦略的SWOT分析
    Oil India Ltd (OIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Taiwan High Speed Rail Corporation
    Taiwan High Speed Rail Corporation - Strategy, SWOT and Corporate Finance Report Summary Taiwan High Speed Rail Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Ultra Electronics 3Phoenix, Inc.:企業の戦略・SWOT・財務情報
    Ultra Electronics 3Phoenix, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ultra Electronics 3Phoenix, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • TearLab Corp (TEAR):医療機器:M&Aディール及び事業提携情報
    Summary TearLab Corp (TearLab) is an ophthalmic device company. It commercializes a proprietary in vitro diagnostic tear testing platform. The company’s flagship TearLab osmolarity system measures the osmolarity of human tears to aid in the diagnosis of dry eye disease (DED) in patients. The company …
  • MorphoSys AG:企業のM&A・事業提携・投資動向
    MorphoSys AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's MorphoSys AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Nippon Yusen Kabushiki Kaisha:企業の戦略・SWOT・財務分析
    Nippon Yusen Kabushiki Kaisha - Strategy, SWOT and Corporate Finance Report Summary Nippon Yusen Kabushiki Kaisha - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Korea Electric Power Corporation:企業の戦略・SWOT・財務情報
    Korea Electric Power Corporation - Strategy, SWOT and Corporate Finance Report Summary Korea Electric Power Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Sheetz, Inc.:企業の戦略・SWOT・財務分析
    Sheetz, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sheetz, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Freudenberg & Co. Kommanditgesellschaft:企業の戦略・SWOT・財務分析
    Freudenberg & Co. Kommanditgesellschaft - Strategy, SWOT and Corporate Finance Report Summary Freudenberg & Co. Kommanditgesellschaft - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Caleres Inc (CAL):企業の財務・戦略的SWOT分析
    Caleres Inc (CAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Guess?, Inc.:戦略・SWOT・企業財務分析
    Guess?, Inc. - Strategy, SWOT and Corporate Finance Report Summary Guess?, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • NHPC Ltd (NHPC)-エネルギー分野:企業M&A・提携分析
    Summary NHPC Ltd. (NHPC), a Government of India Enterprise, is an energy utility that plans, promotes, and organizes integrated development of hydro power plants. The company generates electricity primarily from hydro sources and also harnesses conventional and non-conventional sources such as therm …
  • Ryosan Company, Ltd
    Ryosan Company, Ltd - Strategy, SWOT and Corporate Finance Report Summary Ryosan Company, Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Silverleaf Resorts, Inc.
    Silverleaf Resorts, Inc. - Strategy, SWOT and Corporate Finance Report Summary Silverleaf Resorts, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Power Assets Holdings Limited:企業の戦略・SWOT・財務分析
    Power Assets Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Power Assets Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Oxiteno SA Industria E Comercio:企業の戦略的SWOT分析
    Oxiteno SA Industria E Comercio - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Grifols SA (GRF):製薬・医療:M&Aディール及び事業提携情報
    Summary Grifols SA (Grifols) focuses at improving the health and well-being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company specializes in …
  • Kallpa Generacion SA:企業の戦略的SWOT分析
    Kallpa Generacion SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Kura Oncology Inc (KURA):企業の財務・戦略的SWOT分析
    Summary Kura Oncology Inc (Kura Oncology) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company’s lead drug candidate Tipifarnib, an inhibitor of farnesyl transferase, an oral investigational drug candi …
  • Harris Corp (HRS)-医療機器分野:企業M&A・提携分析
    Summary Harris Corp (Harris) is a communications and information technology company that offers communications products, services and systems, and network solutions. The company offers tactical and land mobile radio systems, IT services, clinically integrated solutions, managed services, government …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆